Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $63.2352W HIGH $130.00
Volume
352.68 K
Value Traded
85.36 M
Short % Float
11.68%
+4.1%Week
-12.18%1 Month
-29.31%3 Month
-9.32%6 Month
+458.44%5 Year
+658.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.63 B
EPS (TTM)
-13.25
P/E Ratio
-
Ent. Value
5.79 B
Total Shares
64.93 M
Float Shares
53.80 M
Insiders
17.14%
Institutions
94.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MIRM Catalyst Timeline
Dated clinical, regulatory and corporate events for Mirum Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mirum Pharmaceuticals, Inc.
310Total events
14Upcoming
122Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutBrelovitugClinical Data
Topline results from Phase 3 AZURE-1 study of Brelovitug in chronic HDV to be shared on investor call
Chronic Hepatitis Deltasource ↗
▲Long Term DataBrelovitugClinical Data
48-week Phase 2b AZURE-1 data show deepening viral suppression and increased ALT normalization
chronic hepatitis delta virus (HDV)source ↗
◆Topline ReadoutBrelovitugClinical Data
Topline results from Phase 3 AZURE-1 study of brelovitug in chronic HDV to be shared on investor call
chronic hepatitis delta virus (HDV)source ↗
▲Primary Endpoint MetBrelovitugClinical Data
Phase 3 AZURE-1 primary endpoint met at Week 24 in chronic HDV
chronic hepatitis delta virus (HDV)source ↗
◆Additional DataBrelovitugClinical Data
48-week data from Phase 2b portion of AZURE-1 study of brelovitug to be shared
chronic hepatitis delta virus (HDV)source ↗
●R&D DayPresentation
Mirum conference call to discuss AZURE-1 topline results
chronic hepatitis delta virus (HDV)source ↗
▲Safety Data UpdateBrelovitugClinical Data
Favorable safety and tolerability profile through Week 24 in Phase 3 AZURE-1; no new safety signals
chronic hepatitis delta virus (HDV)source ↗
◆Full ResultsBrelovitugClinical Data
48-week data from Phase 2b portion of AZURE-1 study of brelovitug to be shared
chronic hepatitis delta virus (HDV)source ↗
▲FDA ApprovalAtebriozApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in adults and pediatric patients ≥12 years
fibrodisplasia ossificante progressiva (FOP)source ↗
▲FDA ApprovalzilurgisertibApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in adults and pediatric patients 12 years and older
fibrodysplasia ossificans progressiva (FOP)source ↗
▲FDA ApprovalzilurgisertibApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for adult and pediatric patients with Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressivasource ↗
▲FDA ApprovalAtebriozApprovedFDA Decision
FDA approves Atebrioz (zilurgisertib) for FOP in patients aged 12 years and older
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
▲PRV GrantedAtebriozApprovedDesignation
FDA issued Rare Pediatric Disease Priority Review Voucher to Incyte
Fibrodysplasia Ossificans Progressiva (FOP)source ↗
◆Topline ReadoutBrelovitugClinical Data
Topline results from AZURE-1 Phase 3 study of brelovitug in chronic HDV expected Q3 2026
chronic hepatitis delta virus (HDV)source ↗
▲Topline ReadoutzilurgisertibApprovedClinical Data
Positive pivotal Phase 2 results from PROGRESS study of Zilurgisertib in FOP
Fibrodysplasia Ossificans Progressivasource ↗
▲Oral PresentationVolixibatPresentation
Late-breaking VISTAS results presented at EASL 2026
primary sclerosing cholangitis (PSC)source ↗
▲Oral PresentationBrelovitugPresentation
Late-breaking Phase 2b AZURE-1 results presented at EASL 2026
chronic hepatitis delta virus (HDV)source ↗
▲Oral PresentationLIVMARLIApprovedPresentation
LIVMARLI data on event-free survival in PFIC presented at EASL 2026
progressive familial intrahepatic cholestasis (PFIC)source ↗
◆Oral PresentationVolixibatPresentation
Volixibat VISTAS full results late-breaking oral presentation at EASL
primary sclerosing cholangitis (PSC)source ↗
◆Poster PresentationBrelovitugPresentation
Brelovitug AZURE-1 full results late-breaking poster at EASL
chronic hepatitis delta virus (HDV)source ↗
▲Primary Endpoint MetVolixibatClinical Data
Volixibat VISTAS Phase 2b met primary endpoint
primary sclerosing cholangitis (PSC)source ↗
▲Primary Endpoint MetBrelovitugClinical Data
Brelovitug Phase 2b portion of AZURE-1 met primary endpoint
chronic hepatitis delta virus (HDV)source ↗
▲Enrollment CompleteBrelovitugTrial
Enrollment completed in brelovitug AZURE-1 and AZURE-4 Phase 3 studies
chronic hepatitis delta virus (HDV)source ↗
▲Enrollment CompleteLIVMARLIApprovedTrial
Enrollment completed in LIVMARLI EXPAND Phase 3 study
additional rare cholestatic conditionssource ↗
▲Partnership / LicensezilurgisertibApprovedCorporate
In-licensed exclusive worldwide rights to zilurgisertib from Incyte
fibrodysplasia ossificans progressiva (FOP)source ↗
▲FDA Filing AcceptedzilurgisertibApprovedRegulatory Filing
FDA accepted NDA for zilurgisertib with Priority Review
fibrodysplasia ossificans progressiva (FOP)source ↗
▲Priority ReviewzilurgisertibApprovedRegulatory Filing
FDA granted Priority Review for zilurgisertib NDA
fibrodysplasia ossificans progressiva (FOP)source ↗
◆Topline ReadoutVolixibatClinical Data
Topline results from VISTAS study of volixibat in PSC
primary sclerosing cholangitissource ↗
◆Topline ReadoutVolixibatClinical Data
Volixibat VISTAS study in PSC topline data expected Q2 2026
primary sclerosing cholangitis (PSC)source ↗
◆Interim AnalysisBrelovitugTrial
Interim data from AZURE-1 expected in Q2 2026
chronic hepatitis delta virussource ↗
◆Topline ReadoutBrelovitugClinical Data
Topline data from AZURE Phase 3 program expected
chronic hepatitis delta virus (HDV)source ↗
◆Pre NDA MeetingVolixibatFDA Meeting
Pre-NDA meeting with FDA for volixibat in PSC scheduled for summer 2026
primary sclerosing cholangitis (PSC)source ↗
▲Enrollment CompleteBrelovitugTrial
AZURE-1 enrollment completed
chronic hepatitis delta virussource ↗
▲Enrollment MilestoneBrelovitugTrial
AZURE-4 screening completed
chronic hepatitis delta virussource ↗
▲Other Regulator MilestoneLIVMARLIApprovedEx-US Regulatory
Health Canada authorization of LIVMARLI for cholestatic pruritus in PFIC patients aged 12 months and older
progressive familial intrahepatic cholestasis (PFIC)source ↗
▲Trial CompletionLIVMARLIApprovedTrial
Phase 3 MARCH study completed and supported Health Canada authorization
progressive familial intrahepatic cholestasis (PFIC)source ↗
▲Partnership / LicenseBrelovitugCorporate
Proposed acquisition of Bluejay Therapeutics to add brelovitug
chronic hepatitis delta virus (HDV)source ↗
▲Primary Endpoint MetVolixibatClinical Data
VISTAS study met primary endpoint with statistically significant pruritus reduction
primary sclerosing cholangitis (PSC)source ↗
▲Primary Endpoint MetBrelovitugClinical Data
AZURE-1 Phase 2b met primary composite endpoint at Week 24
chronic hepatitis delta virus (HDV)source ↗
Past FDA Catalysts and PDUFA Decisions
How MIRM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-25 | Zilurgisertib | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$1.5B
Pipeline Value
$2.7B
Commercial Value
Overvalued
Valuation Signal
6
Drugs Scored
0.5x
rNPV / MCap
Top 11%
Small Cap(rank 73 of 658)
Percentile Rank
Mirum Pharmaceuticals, Inc. carries a moderate pipeline score (56/100), with $2.2B risk-adjusted pipeline value, led by Blinded CDCA in CTX (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $618.1M x 4.4 = $2.7B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Livmarli | $441M | $285M | +55% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blinded CDCA Small moleculeCompletedNCT04270682 | CTX | Phase 3 | COMPLETED | 19 | Oct 4, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every MIRM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| brelovitug | Chronic Hepatitis Delta Virus | Phase 3 | 2026-09-28 | 300 mg QW arm: 56%; 900 mg Q4W arm: 45%; delayed treatment arm: 0%; p value: <0.0001Read More | Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Peetz ChristopherDirector, Officer (CHIEF EXECUTIVE OFFICER) | Option | 5,305 199,745 held | $19.19 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MIRM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 19.6 % (7.1 %) | 899.06 M | 7.68 M |
MIRM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MIRM ranks across every disease it competes in
Competitive Position is a premium feature
See how MIRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMIRM News
MIRMResumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta
Mirum Pharmaceuticals has announced the successful achievement of the primary endpoint in the Phase III AZURE-1 study. This study evaluates brelovitug, a fully human monoclonal antibody targeting the hepatitis B surface antigen, for treating chronic hepatitis delta virus infection. The results could pave the way for new treatment options in this area.
Read more →MIRMMirum Pharmaceuticals gibt bekannt, dass der primäre Endpunkt in der Phase-3-Studie AZURE-1 zu Brelovitug bei chronischer Hepatitis-Delta-Virus-Infektion erreicht wurde
Mirum Pharmaceuticals announced that the primary endpoint in the Phase 3 AZURE-1 study was achieved. The study evaluates Brelovitug, a fully human monoclonal antibody targeting Hepatitis B surface antigen, for the treatment of chronic Hepatitis Delta Virus infection. This milestone marks a significant advancement in the company's clinical development efforts.
Read more →MIRMSamenvatting: Mirum Pharmaceuticals maakte bekend dat het primaire eindpunt is bereikt in de Fase 3 AZURE-1 studie van brelovitug bij chronische hepatitis delta-virus
Mirum Pharmaceuticals announced that the primary endpoint has been met in the Phase 3 AZURE-1 study evaluating brelovitug. This fully human monoclonal antibody targets HBsAg for treating chronic hepatitis delta virus (HDV). The achievement marks a significant milestone in the development of therapies for rare diseases.
Read more →MIRMRiassunto: Mirum Pharmaceuticals annuncia che brelovitug ha raggiunto l'endpoint primario dello studio di Fase 3 AZURE-1 per il trattamento del virus dell'epatite cronica Delta
Mirum Pharmaceuticals announced that brelovitug has successfully reached the primary endpoint in the Phase 3 AZURE-1 clinical trial. This study evaluates brelovitug, a fully human monoclonal antibody targeting the hepatitis B surface antigen, for treating chronic Delta hepatitis. The achievement marks a significant milestone for the company in addressing rare diseases.
Read more →MIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals announced that the primary endpoint was met in its Phase 3 AZURE-1 study of Brelovitug for Chronic Hepatitis Delta Virus. This achievement indicates the potential effectiveness of Brelovitug in treating this challenging condition. The results may lead to improved treatment options for patients suffering from this virus.
Read more →MIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals announced an upcoming investor call scheduled for September 28, 2026, to discuss the topline results from the Phase 3 AZURE-1 study of Brelovitug in patients with chronic hepatitis delta virus (HDV). This study represents a critical advancement in the treatment options available for this condition.
Read more →MIRMRiassunto: Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP)
Mirum Pharmaceuticals and Incyte have received FDA approval for Atebrioz™ (zilurgisertib) to treat patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). This approval marks a significant advancement in the treatment options available for this rare condition, focusing on reducing total heterotopic ossification volume.
Read more →MIRMSamenvatting: Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva
Mirum Pharmaceuticals and Incyte announced that the FDA has approved Atebrioz™ (zilurgisertib) for patients aged 12 and older with fibrodysplasia ossificans progressiva. This approval aims to reduce the total volume of new heterotopic ossification in affected individuals. The approval marks a significant advancement in treatment options for this rare condition.
Read more →MIRMResumen: Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva
Mirum Pharmaceuticals and Incyte have announced that the FDA has approved Atebrioz™ (zilurgisertib) for the treatment of heterotopic ossification in patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). This approval marks a significant advancement in treatment options for this rare condition, providing new hope for patients and their families.
Read more →MIRMMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have received U.S. FDA approval for Atebrioz™ (zilurgisertib), a treatment for both adult and pediatric patients suffering from Fibrodysplasia Ossificans Progressiva (FOP). This approval marks a significant advancement in addressing the needs of patients with this rare condition. The collaboration highlights the commitment of both companies to develop innovative therapies.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This announcement is part of their compliance with regulatory requirements. Details regarding the specific nature of the grants were not provided in the report.
Read more →MIRMMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals has appointed Dr. Rob Myers as its new Chief Medical Officer. This strategic move is expected to leverage Dr. Myers' extensive experience in the biopharma industry. The appointment reflects the company's commitment to advancing its medical initiatives and improving its leadership team.
Read more →MIRMMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals has announced its participation in upcoming investor conferences. This engagement suggests a proactive approach to maintaining investor relations and sharing potential updates about the company's developments. Such participation is often seen as a positive indicator of a company's transparency and growth strategy.
Read more →MIRM▼ -11%on this news
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals has released its financial results for the second quarter of 2026, along with a business update. The report highlights key financial metrics and strategic initiatives. Further details on the company's performance and future plans were also shared.
Read more →MIRMMirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Mirum Pharmaceuticals has scheduled a conference call to announce its financial results for the second quarter of 2026. The call will take place on August 5, 2026. This event is part of the company's regular financial reporting.
Read more →MIRMMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have announced positive results from the pivotal Phase 2 PROGRESS study of Zilurgisertib, a treatment for Fibrodysplasia Ossificans Progressiva (FOP). The study's findings indicate potential benefits for patients suffering from this rare condition. This development could pave the way for further advancements in treatment options.
Read more →MIRM▼ -5.1%on this news
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals presented new data at the EASL International Liver Congress 2026, showcasing promising results from its rare liver disease programs. The Phase 2b VISTAS study indicated that volixibat significantly reduces pruritus in primary sclerosing cholangitis (PSC). Additionally, the AZURE-1 study demonstrated the efficacy and safety of brelovitug for chronic hepatitis delta virus (HDV). LIVMARLI also showed improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC).
Read more →About Mirum Pharmaceuticals, Inc.
Headquarters989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next MIRM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime